SGLT-2抑制增加内源性葡萄糖生成源于糖异生而非糖原分解
本研究在健康志愿者和2型糖尿病患者中,单次给予达格列净或安慰剂,用磁共振波谱和示踪技术评估肝糖原分解、糖异生及肝细胞脂质和线粒体活性。结果显示,SGLT-2抑制后内源性葡萄糖生成增加由糖异生增强所致,而非糖原分解,且肝细胞脂质和线粒体活性无显著变化。
要点
- SGLT-2抑制后内源性葡萄糖生成增加由糖异生增强介导,而非糖原分解。
- 健康志愿者中达格列净使内源性葡萄糖生成升高,且与尿糖排泄强相关。
- 单次达格列净未显著影响肝细胞脂质含量和线粒体活性。
核心结论
- SGLT-2抑制后内源性葡萄糖生成升高由糖异生增加所致,而非糖原分解。
- 胰高血糖素及胰岛素/胰高血糖素比值变化与肝糖原分解增加无关。
- 单次达格列净未显著影响肝细胞脂质含量和线粒体活性。
研究设计与样本
- 研究纳入10名健康志愿者和6名2型糖尿病患者,随机接受单次10 mg达格列净或安慰剂。
- 采用1H/13C/31P磁共振波谱在给药前、90-180分钟和300-390分钟评估肝糖原分解、肝细胞脂质和线粒体活性。
- 采用示踪稀释技术评估内源性葡萄糖生成。
主要发现
- 健康志愿者中,达格列净组内源性葡萄糖生成高于安慰剂组(12.4 ± 0.5 vs 10.0 ± 0.3 μmol kg-1 min-1;P < 0.05)。
- 2型糖尿病患者中,达格列净组与安慰剂组内源性葡萄糖生成无显著差异(10.1 ± 0.7 vs 10.4 ± 0.5 μmol kg-1 min-1;P = n.s.)。
- 内源性葡萄糖生成与尿糖排泄强相关(r = 0.732;P < 0.01)。
- 健康志愿者和2型糖尿病患者达格列净后胰岛素/胰高血糖素比值较基线降低(P < 0.05)。
- 健康志愿者中,达格列净组糖异生高于安慰剂组(9.9 ± 0.6 vs 6.7 ± 0.6 μmol kg-1 min-1;P < 0.01),糖原分解无显著差异。
临床怎么用
- SGLT-2抑制剂降糖效果可能部分被糖异生增加所抵消,临床关注其与抑制糖异生药物的联合策略。
- 单次达格列净未显著影响肝细胞脂质和线粒体活性,短期肝脏能量代谢影响有限。
局限性
- 样本量小(健康志愿者10名,2型糖尿病患者6名),研究为单次给药急性效应。
- 2型糖尿病患者中糖异生变化未达统计学显著,可能受样本量限制。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Recent studies indicate that sodium-glucose cotransporter 2 (SGLT-2) inhibition increases endogenous glucose production (EGP), potentially counteracting the glucose-lowering potency, and stimulates lipid oxidation and lipolysis. However, the acute effects of SGLT-2 inhibition on hepatic glycogen, lipid, and energy metabolism have not yet been analyzed. We therefore investigated the impact of a single dose of dapagliflozin (D) or placebo (P) on hepatic glycogenolysis, hepatocellular lipid (HCL) content and mitochondrial activity (kATP). RESEARCH DESIGN AND METHODS: Ten healthy volunteers (control [CON]: age 30 ± 3 years, BMI 24 ± 1 kg/m2, HbA1c 5.2 ± 0.1%) and six patients with type 2 diabetes mellitus (T2DM: age 63 ± 4 years, BMI 28 ± 1.5 kg/m2, HbA1c 6.1 ± 0.5%) were investigated on two study days (CON-P vs. CON-D and T2DM-P vs. T2DM-D). 1H/13C/31P MRS was performed before, 90-180 min (MR1), and 300-390 min (MR2) after administration of 10 mg dapagliflozin or placebo. EGP was assessed by tracer dilution techniques. RESULTS: Compared with CON-P, EGP was higher in CON-D (10.0 ± 0.3 vs. 12.4 ± 0.5 μmol kg-1 min-1; P < 0.05) and comparable in T2DM-D and T2DM-P (10.1 ± 0.7 vs. 10.4 ± 0.5 μmol kg-1 min-1; P = not significant [n.s.]). A strong correlation of EGP with glucosuria was observed (r = 0.732; P < 0.01). The insulin-to-glucagon ratio was lower after dapagliflozin in CON-D and T2DM-D compared with baseline (P < 0.05). Glycogenolysis did not differ between CON-P and CON-D (-3.28 ± 0.49 vs. -2.53 ± 0.56 μmol kg-1 min-1; P = n.s.) or T2DM-P and T2DM-D (-0.74 ± 0.23 vs. -1.21 ± 0.33 μmol kg-1 min-1; P = n.s.), whereas gluconeogenesis was higher after dapagliflozin in CON-P compared with CON-D (6.7 ± 0.6 vs. 9.9 ± 0.6 μmol kg-1 min-1; P < 0.01) but not in T2DM. No significant changes in HCL and kATP were observed. CONCLUSIONS: The rise in EGP after SGLT-2 inhibition is due to increased gluconeogenesis, but not glycogenolysis. Changes in glucagon and the insulin-to-glucagon ratio are not associated with an increased hepatic glycogen breakdown. HCL and kATP are not significantly affected by a single dose of dapagliflozin.
引用
- Wolf P, Fellinger P, Pfleger L, et al. Gluconeogenesis, But Not Glycogenolysis, Contributes to the Increase in Endogenous Glucose Production by SGLT-2 Inhibition. Diabetes Care. 2020. PMID: 33318126. doi:10.2337/dc20-1983
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。